MedWatch

Lundbeck's migraine drug approved in EU

Vyepti has become the first approved intravenous preventative migraine treatment in the region.

Photo: Lundbeck / PR

Lundbeck’s migraine drug Vyepti has been approved for use in the EU, the company reports in a press release.

”We have high expectations for Vyepti and with the EU approval, we look forward to providing a much-needed treatment option to millions of patients and provide the possibility of reducing the medical and personal burden of migraine which otherwise immensely impair the family, social, and work life of these patients,” says Johan Luthman, EVP and Head of Research & Development, in the press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs